Sagittarius Life Science

Sagittarius Life Science Current Liabilities

The Current Liabilities of Sagittarius Life Science (3205.TWO) as of Oct 31, 2026 is 10.27 M TWD. In the previous year, Current Liabilities was 68.30 M TWD — a change of -84.96% (lower).

Current Liabilities

10.27 MTWD

YoY

-84.96%

Last updated:

Current Liabilities of Sagittarius Life Science is 2025 10.27 M TWD. Current Liabilities of Sagittarius Life Science was 2024 68.30 M TWD. It decreases by -84.96% lower compared to the previous year.

The Sagittarius Life Science Current Liabilities history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Current Liabilities
Date
Current Liabilities
Jan 1, 2018
90.77 M TWD
Jan 1, 2019
108.79 M TWD
Jan 1, 2020
92.43 M TWD
Jan 1, 2021
106.13 M TWD
Jan 1, 2022
95.94 M TWD
Jan 1, 2023
106.57 M TWD
Jan 1, 2024
68.30 M TWD
Jan 1, 2025
10.27 M TWD
The Sagittarius Life Science Current Liabilities history
YEARCurrent LiabilitiesYoY
10.27 MTWD-84.96%
68.30 MTWD-35.91%
106.57 MTWD+11.08%
95.94 MTWD-9.61%
106.13 MTWD+14.83%
92.43 MTWD-15.04%
108.79 MTWD+19.86%
90.77 MTWD-0.91%
91.61 MTWD-61.15%
235.82 MTWD-32.27%
348.18 MTWD+147.97%
140.42 MTWD+135.48%
59.63 MTWD-18.60%
73.26 MTWD+23.34%
59.39 MTWD-50.26%
119.40 MTWD+104.59%
58.36 MTWD+212.02%
18.70 MTWD-26.39%
25.41 MTWD-47.82%
48.70 MTWD+146.89%
19.72 MTWD-5.68%
20.91 MTWD+122.49%
9.40 MTWD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Sagittarius Life Science Stock analysis

What does Sagittarius Life Science do? Sagittarius Life Science Corp. generates revenue through the manufacture and sale of Chinese and western medicine, including nutrition and health formulations, natural and organic food, beverages, probiotic fermentation products, beauty care ingredients, Chinese herbal medicines, plant new medicines, and health supplies. The company serves domestic markets in Taiwan and overseas markets in Asia and the Americas, distributing its products through established channels. Technical services for pharmaceutical R&D are also a key revenue stream, supporting clients in developing both traditional and modern medicine solutions. The firm's product portfolio targets health-conscious consumers seeking natural and organic solutions, as well as businesses in the pharmaceutical and beauty care industries requiring specialized ingredients and formulations. Domestic sales focus on Taiwan, while international distribution extends to Asian regions outside of Taiwan and the Americas, reflecting a strategic market expansion. Revenue is derived from direct product sales and technical service contracts, with no mention of third-party partnerships or additional revenue streams beyond the described offerings. Sagittarius Life Science is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Sagittarius Life Science stock

Current Liabilities of Sagittarius Life Science is 10.27 M TWD in 2025.

Current Liabilities of Sagittarius Life Science changed from 68.30 M TWD to 10.27 M TWD, representing a -84.96% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Current Liabilities Sagittarius Life Science since 2006 – with annual values, charts, and detailed analysis.

Current liabilities are obligations due within one year, including accounts payable, short-term debt, and accrued expenses.

Current Liabilities's TWD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Current Liabilities's Sagittarius Life Science historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Sagittarius Life Science

All Key Metrics — Sagittarius Life Science